- Product
- Listing first-line lung cancer treatment Tagrisso 'deferred'
- by Byun Kyung A Oct 31, 2019 09:35am
- A first-line anticancer therapy, Tagrisso could struggle to get listed for NHI reimbursement. An industry insider reported on Oct. 17, Health Insurance Review and Assessment Service (HIRA) Cancer Disease Deliberation Committee decided to ‘defer’ on the decision to list Tagrisso (osimertinib), a third generation Epidermal Growth Factor
